genome particles of AAV.sFlt-1 was administered by a single injection under the peripheral retina in two groups of three patients (avoiding the central macula). The hypothesis is that transduced cells will produce sufficient sFlt-1 protein to diffuse into the vitreous and inactivate VEGF. 4 Treatment effects were assessed by a reduction in the need for further injections of the standard treatment (ranibizumab) and improvements in retinal anatomy during the one year study period. Whilst there was no matched control group, comparisons to historical data from other studies was in keeping with a treatment effect from the procedure. There were no safety concerns, such as retinal ischaemia or atrophy of the retinal tissue, which has been a concern with prolonged anti-VEGF therapy. 5 This trial is notable in exploring the use of gene therapy as a means of providing a 'protein pump', which is particularly suited to the enclosed compartment of the eye. Whilst AAV gene therapy is established for gene replacement in single gene disorders, 6 the use of gene therapy to reprogram genetically normal cells of the retina to take on additional functions opens a new chapter in potential AAV applications. One of the very first retinal gene therapy trials also used a viral vector as a pharmacological tool for the sustained delivery of a therapeutic protein to block VEGF in AMD. 7 The key difference between that and the current trial is that the former study used an adenoviral (Ad) vector to deliver the VEGF antagonist, which was predicted to have only a temporary effect. 7 Adeno-associated viral (AAV) vectors, in contrast, have evolved to evade the host immune system and have shown evidence of indefinite gene expression following human subretinal administration. 8 Other anti-VEGF approaches in clinical trials include administering the AAV vector directly into the vitreous cavity rather than into the subretinal space (NCT01024998). Intravitreal injections are easier to perform, but most likely a higher vector dose would be needed and there could be more off-target effects due to transducing retinal ganglion cells and a greater risk of inflammation. 9 The current study validates the subretinal approach. There are however outstanding questions, such as which promoter to use.
Although not stated in this paper, the preclinical study of AAV.sFlt-1 used the cytomegalovirus (CMV) promoter, 10 which can be subject to longterm silencing in the brain. 11 Similarly it remains to be seen if a surgically-implanted slow release device, which is also currently in clinical trial, 12 may yield more predictable levels of VEGF inhibition compared with gene therapy. In this regard, it would be helpful to know the variability in intravitreal levels of sFlt-1 when delivered by gene therapy. Where gene therapy has an unrivalled advantage over slow release devices, however, is when proteins need to be expressed within the cytoplasm of the cells in order to have a therapeutic effect. In AMD the ideal goal would be to prevent the disease altogether using AAV gene therapy, possibly by correcting genes encoding complement proteins with a single subretinal administration. That would be as close to a cure for AMD as we could get. 
